Roche, Basel, Switzerland)/dispase-II (2.4 units/mL
In clinical and preclinical research, Melanotan I has been observed to modulate UV-response pathways and photoprotective pigmentation mechanisms
The comparator groups differed among studies, with some employing placebo controls (e.g., PIONEER-6, Gerstein 2019), others using active comparators such as sitagliptin, glimepiride, DPP-4 inhibitors, or SGLT2 inhibitors, and some utilizing standard care or intensive lifestyle interventions as the control
Administer GONAL-f subcutaneously in the abdomen, upper arm, or upper leg as described in Patient Information and Instructions for Use
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study